| 臺大學術典藏 |
2021-10-18T06:30:00Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; YEN-NIEN CHEN; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-10-18T06:30:00Z |
Systematic review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Chen M.-J.; Chen C.-C.; YEN-NIEN CHEN; Chen C.-C.; Fang Y.-J.; Lin J.-T.; Wu M.-S.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-10-18T06:29:59Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; YEN-NIEN CHEN; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-10-18T06:29:58Z |
Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan
|
Chen M.-J.; Fang Y.-J.; Wu M.-S.; Chen C.-C.; YEN-NIEN CHEN; Yu C.-C.; Kuo C.-C.; Chiu M.-C.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen H.-H.; Bair M.-J.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-10-18T06:29:58Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; YEN-NIEN CHEN; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-09-15T06:19:21Z |
Community-Based Gastric Cancer Screening Coupled With a National Colorectal Cancer Screening Program: Baseline Results
|
Lee Y.-C.; Chiang T.-H.; Chiu H.-M.; Wu M.-S.; Yeh Y.-P.; Hsiu-Hsi Chen T.; Li-Sheng Chen S.; Ming-Fang Yen A.; Ching-Yuan Fann J.; Yueh-Hsia Chiu S.; Hsu C.-Y.; Chuang S.-L.; Chou K.-C.; Su W.-W.; Chen S.-T.; Liao C.-S.; Lin Y.-M.; Chang H.-C.; Hu T.-H.; Fang Y.-J.; CHANG-CHUAN CHAN; Collaborators of the Taiwan Community-Based Integrated Screening Group |
| 臺大學術典藏 |
2021-09-04T06:11:10Z |
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; JIA-HORNG KAO; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; Chen C.-C.; Fang Y.-J.; Hung H.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2021-09-04T06:10:55Z |
Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Fang Y.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:49Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:46Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:42Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:25Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:17Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-01T01:54:03Z |
Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma
|
Yang S.-H.; Lin L.-W.; Fang Y.-J.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-12T04:01:30Z |
Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma
|
YANG SHIH-HUNG; Lin L.-W.; Fang Y.-J.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-10T03:53:06Z |
Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma
|
SHIH-HUNG YANG; Lin L.-W.; Fang Y.-J.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:43Z |
Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Fang Y.-J.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:31Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.;Shih Y.-L.;Yang S.-S.;Lin C.-L.;Fang Y.-J.;Cheng P.-N.;Chen C.-Y.;Peng C.-Y.;Hsieh T.-Y.;Chiu Y.-C.;Su T.-H.;Liu C.-J.;Yang H.-C.;Pei-Jer Chen;Chen D.-S.;Kao J.-H.; Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:20Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-27T08:21:00Z |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multicentre clinical trial
|
JYH-MING LIOU; Chen C.-C.; Chen M.-J.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Sheng W.-H.; Wang H.-P.; Wu M.-S.; Lin J.-T. |
| 臺大學術典藏 |
2021-05-27T08:20:59Z |
Randomised clinical trial: High-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers
|
Chen C.-C.; Lee J.-Y.; Fang Y.-J.; Hsu S.-J.; Han M.-L.; Tseng P.-H.; JYH-MING LIOU; Hu F.-C.; Lin T.-L.; Wu M.-S.; Wang H.-P.; Lin J.-T. |
| 臺大學術典藏 |
2021-05-27T08:20:58Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
JYH-MING LIOU; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2021-05-27T08:20:57Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
JYH-MING LIOU; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2021-05-27T08:20:53Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; JYH-MING LIOU; Chen C.-C.; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; Chen C.-C.; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2021-05-27T08:20:53Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
JYH-MING LIOU; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-27T08:20:51Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
JYH-MING LIOU; Bair M.-J.; Chen C.-C.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2021-05-27T08:20:49Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
JYH-MING LIOU; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-27T08:20:49Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
JYH-MING LIOU; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-27T08:20:47Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; Chen C.-C.; Chen C.-C.; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; JYH-MING LIOU; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-27T08:20:45Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
JYH-MING LIOU; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; JYH-MING LIOU; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-27T08:20:45Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
JYH-MING LIOU; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-27T08:20:44Z |
Systematic review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Chen M.-J.; Chen C.-C.; Chen Y.-N.; Chen C.-C.; Fang Y.-J.; Lin J.-T.; Wu M.-S.; JYH-MING LIOU; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-27T08:20:42Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
JYH-MING LIOU; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-27T08:20:41Z |
Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan
|
Chen M.-J.; Fang Y.-J.; Wu M.-S.; Chen C.-C.; Chen Y.-N.; Yu C.-C.; Kuo C.-C.; Chiu M.-C.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen H.-H.; Bair M.-J.; JYH-MING LIOU; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-24T07:20:30Z |
Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection
|
CHEN-HUA LIU; Liu C.-J.; Su T.-H.; Fang Y.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:21Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
CHEN-HUA LIU; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:20Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
CHEN-HUA LIU; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:14Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
CHEN-HUA LIU; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:13Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
CHEN-HUA LIU; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?�Y.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-14T05:40:09Z |
Computer-generated surface and tone enhancements to distinguish neoplastic from non-neoplastic colon polyps less than 1 cm in diameter
|
MING-LUN HAN; Lee Y.-C.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Lin T.-L.; Lin L.-W.; Tseng P.-H.; Wu M.-S.; Wang H.-P. |
| 臺大學術典藏 |
2021-05-14T05:40:08Z |
Randomised clinical trial: High-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers
|
Chen C.-C.; Lee J.-Y.; Fang Y.-J.; Hsu S.-J.; MING-LUN HAN; Tseng P.-H.; Liou J.-M.; Hu F.-C.; Lin T.-L.; Wu M.-S.; Wang H.-P.; Lin J.-T. |
| 臺大學術典藏 |
2021-05-07T05:13:24Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; CHING-CHOW CHEN; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; CHING-CHOW CHEN; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease and Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-07T02:06:14Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; CHIH-HSIEN WANG; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2021-05-06T01:25:13Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; CHIEN-CHING HUNG; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; Kao J.-H. |
| 臺大學術典藏 |
2021-04-15T06:33:49Z |
Suggested cutoff tumor size for management of small EUS-suspected gastric gastrointestinal stromal tumors
|
Fang Y.-J.; Cheng T.-Y.; Sun M.-S.; Yang C.-S.; Chen J.-H.; WEI-CHIH LIAO; Wang H.-P. |
| 臺大學術典藏 |
2021-03-29T06:08:22Z |
Comparison of DNA stabilizers and storage conditions on preserving fecal microbiota profiles
|
Chen, C.-C.; Wu, W.-K.; Chang, C.-M.; Panyod, S.; Lu, T.-P.; Liou, J.-M.; Fang, Y.-J.; Chuang, E.Y.; Wu, M.-S.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2021-03-29T06:08:21Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou, J.-M.; Chen, C.-C.; Chang, C.-M.; Fang, Y.-J.; Bair, M.-J.; Chen, P.-Y.; Chang, C.-Y.; Hsu, Y.-C.; Chen, M.-J.; Chen, C.-C.; Lee, J.-Y.; Yang, T.-H.; Luo, J.-C.; Chen, C.-Y.; Hsu, W.-F.; Chen, Y.-N.; Wu, J.-Y.; Lin, J.-T.; Lu, T.-P.; Chuang, E.Y.; El-Omar, E.M.; Wu, M.-S.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2021-03-18T02:02:50Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.;Chen C.-C.;Chang C.-Y.;Chen M.-J.;Fang Y.-J.;Lee J.-Y.;Chen C.-C.;Hsu S.-J.;Hsu Y.-C.;Tseng C.-H.;Tseng P.-H.;Chang L.;Chang W.-H.;Wang H.-P.;Chia-Tung Shun;Wu J.-Y.;Lee Y.-C.;Lin J.-T.;Wu M.-S.;Lin C.-H.;Chow L.-P.;Cheng T.-Y.;Wu C.-Y.;Lee Ching-Tai C.-T, Wang W.-L.;Tai C.-M.;Wang Y.-C.;Wang C.-H.;Kuo S.-H.;Wu C.-Y.; Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; CHIA-TUNG SHUN; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2021-03-18T02:02:50Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.;Chen C.-C.;Chen M.-J.;Chen C.-C.;Chang C.-Y.;Fang Y.-J.;Lee J.-Y.;Hsu S.-J.;Luo J.-C.;Chang W.-H.;Hsu Y.-C.;Tseng C.-H.;Tseng P.-H.;Wang H.-P.;Yang U.-C.;Chia-Tung Shun;Lin J.-T.;Lee Y.-C.;Wu M.-S.; Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; CHIA-TUNG SHUN; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2021-03-18T02:02:40Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; Chen C.-C.; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; Chen C.-C.; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; CHIA-TUNG SHUN; Wu M.-S. |
